Diabetes in the Bariatric Surgery Patient

  • Panduranga Yenumula
  • Carolina Gomes Goncalves
  • Stacy A. Brethauer
  • Sangeeta Kashyap
  • Philip R. Schauer


According to the recently updated National Diabetes Statistics Fact Sheet, an estimated 18.2 million people, or approximately 6.3% of the United States population, have diabetes. Of those, 13 million are diagnosed with overt diabetes and 5.2 million are undiagnosed. Each year, approximately 1.3 million persons aged 20 years or older are diagnosed with the disease.


Bariatric Surgery Gastric Bypass Laparoscopic Adjustable Gastric Banding Ghrelin Level Bariatric Surgery Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006;295(13):1549–1555.CrossRefPubMedGoogle Scholar
  2. 2.
    Flegal K, Carroll M, Kuczmarski R, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Dis 1998;22:39–47.CrossRefGoogle Scholar
  3. 3.
    Harris M, Flegal K, Cowie C, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 1998;21:518–524.CrossRefPubMedGoogle Scholar
  4. 4.
    National Task Force on the Prevention and Treatment of Obesity. Over-weight, obesity, and health risk. Arch Intern Med 2000;160:898–904.CrossRefGoogle Scholar
  5. 5.
    Nathan D. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342–1349.CrossRefPubMedGoogle Scholar
  6. 6.
    Panzram G. Mortality and survival in type 2 (non-insulindependent) diabetes mellitus. Diabetologia 1998;30:123–131.CrossRefGoogle Scholar
  7. 7.
    Rubin R, Altman W, Mendelson D. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994;78:809A–809F.CrossRefPubMedGoogle Scholar
  8. 8.
    American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002;25(suppl 1):S5–S20.Google Scholar
  9. 9.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(suppl 1): S43–S48.Google Scholar
  10. 10.
    Atkinson MA, Maclaren NK. The pathogenesis of insulindependent diabetes mellitus. N Engl J Med 1994;331: 1428–1436.CrossRefPubMedGoogle Scholar
  11. 11.
    Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000;342:301–307.CrossRefPubMedGoogle Scholar
  12. 12.
    Lager I, Lonnroth P, von Schenck H, Smith U. Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion. Br Med J (Clin Res Ed) 1983;287:1661–1664.CrossRefGoogle Scholar
  13. 13.
    DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 1982;31:795–801.CrossRefPubMedGoogle Scholar
  14. 14.
    Yki-Jarvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. N Engl J Med 1986;315:224–230.CrossRefPubMedGoogle Scholar
  15. 15.
    DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982;23:313–319.CrossRefPubMedGoogle Scholar
  16. 16.
    Samaras K, Nguyen TV, Jenkins AB, et al. Clustering of insulin resistance, total and central abdominal fat: same genes or same environment? Twin Res 1999;2:218–225.CrossRefPubMedGoogle Scholar
  17. 17.
    Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45:633–638.CrossRefPubMedGoogle Scholar
  18. 18.
    Kabadi UM, Vora A, Kabadi M. Hyperinsulinemia and central adiposity: influence of chronic insulin therapy in type 1 diabetes. Diabetes Care 2000;23:1024–1025.CrossRefPubMedGoogle Scholar
  19. 19.
    Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing’s disease of the omentum”? Lancet 1997; 349:1210–1213.CrossRefPubMedGoogle Scholar
  20. 20.
    Pernet A, Trimble ER, Kuntschen F, et al. Insulin resistance in Type 1 (insulin-dependent) diabetes: dependence on plasma insulin concentration. Diabetologia 1984;26:255–260.CrossRefPubMedGoogle Scholar
  21. 21.
    Shahady E. Exercise as medication: how to motivate your patients. Consultant 2000;40:2174–2178.Google Scholar
  22. 22.
    Levey AS, Adler S, Caggiula AW, et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1996;27:652–663.CrossRefPubMedGoogle Scholar
  23. 23.
    Koivisto VA, DeFronzo RA. Physical training and insulin sensitivity. Diabetes Metab Rev 1986;1:445–481.CrossRefPubMedGoogle Scholar
  24. 24.
    DeFronzo RA, Ferrannini E, Sato Y, et al. Synergistic interaction between exercise and insulin on peripheral glucose uptake. J Clin Invest 1981;68:1468–1474.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.CrossRefPubMedGoogle Scholar
  26. 26.
    Dixon JB, Pories WJ, O’Brien PE, Schauer PR, Zimmet P. Surgery as an effective early intervention for diabesity: Why the reluctance? Diabetes Care 2005;28:472–474.CrossRefPubMedGoogle Scholar
  27. 27.
    Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.Google Scholar
  28. 28.
    The relationship of glycemic exposure (HbA sub1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44: 968–983.Google Scholar
  29. 29.
    Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulindependent diabetes mellitus. N Engl J Med 1991;325(3): 147–152.CrossRefPubMedGoogle Scholar
  30. 30.
    Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287:360–372.CrossRefPubMedGoogle Scholar
  31. 31.
    American Diabetes Association. The pharmacologic treatment of hyperglycemia in NIDDM. Diabetes Care 1995;18: 1510–1518.CrossRefGoogle Scholar
  32. 32.
    Halford JC. Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Curr Drug Targets 2004;5:637–646.CrossRefPubMedGoogle Scholar
  33. 33.
    Uusitupa MIJ. Early lifestyle intervention in patients with non-insulin dependent diabetes mellitus and impaired glucose tolerance. Ann Med 1996;28:445–449.CrossRefPubMedGoogle Scholar
  34. 34.
    Pan X, Li G, Hu Y, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537–544.CrossRefPubMedGoogle Scholar
  35. 35.
    Redmon J, Raatz S, Kwong C, et al. Pharmacologic induction of weight loss to treat type 2 diabetes. Diabetes Care 1999;22:896–903.CrossRefPubMedGoogle Scholar
  36. 36.
    Paisey R, Frost J, Harvey A, et al. Five year results of a prospective very low calorie diet or conventional weight loss programme in type 2 diabetes. J Hum Nutr Dietet 2002;15:121–127.CrossRefGoogle Scholar
  37. 37.
    Metz J, Stern JS, Kris-Etherton P, et al. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000;160:2150–2158.CrossRefPubMedGoogle Scholar
  38. 38.
    Agurs-Collins T, Kumanyika S, Ten Have T, et al. A randomized controlled trial of weight reduction and exercise for diabetes management in older African American subjects. Diabetes Care 1997;20:1503–1511.CrossRefPubMedGoogle Scholar
  39. 39.
    Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes, Obesity and Metaboism, 2003;5:180–188.CrossRefGoogle Scholar
  40. 40.
    Shi YF, Pan CY, Hill J, Gao Y Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. Diabet Med 2005;22:1737–1743.CrossRefPubMedGoogle Scholar
  41. 41.
    Johnson D, Drenick EJ. Therapeutic fasting in morbid obesity. Arch Intern Med 1977;137:1381–1382.CrossRefPubMedGoogle Scholar
  42. 42.
    Andersen T, Backer OG, Stokholm KH, et al. Randomized trial of diet and gastroplasty compared with diet alone in morbid obesity. N Engl J Med 1984;310:352–356.CrossRefPubMedGoogle Scholar
  43. 43.
    NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. Ann Intern Med 1992;116:942–949.CrossRefGoogle Scholar
  44. 44.
    Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339–352.PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238:467–484; discussion 484–485.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Crookes PF. Surgical treatment of morbid obesity. Annu Rev Med 2006;57:243–264.CrossRefPubMedGoogle Scholar
  47. 47.
    Sugerman HJ, Wolfe LG, Sica DA, Clore JN Diabetes and hypertension in severe obesity and effects of gastric bypassinduced weight loss. Ann Surg 2003;237:751–756; discussion 757–758.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y—500 patients: technique and results, with 3–60 month follow-up. Obes Surg 2000;10:233–239.CrossRefPubMedGoogle Scholar
  49. 49.
    Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232:515–529.PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Torquati A, Lutfi R, Abumrad N, Richards WO. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg 2005;9:1112–1116.CrossRefPubMedGoogle Scholar
  51. 51.
    Long SD, O’Brien K, MacDonald KG Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 1994;17:372–375.CrossRefPubMedGoogle Scholar
  52. 52.
    Pasquali R, Vicennati V, Scopinaro N, et al. Achievement of near-normal body weight as the prerequisite to normalize sex hormone-binding globulin concentrations in massively obese men. Int J Obes 1997;21:1–5.CrossRefGoogle Scholar
  53. 53.
    Sjostrom C, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999;7:477–484.CrossRefPubMedGoogle Scholar
  54. 54.
    Dixon JB, O’Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002;25:358–363.CrossRefPubMedGoogle Scholar
  55. 55.
    Pontiroli A Pizzocri P, Librenti M, et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three year study. J Clin Endocrinol Metab 2002;87:3555–3561.CrossRefPubMedGoogle Scholar
  56. 56.
    Marceau P, Hould FS, Simard S, et al. Biliopancreatic diversion with duodenal switch. World J Surg 1998;22:947–954.CrossRefPubMedGoogle Scholar
  57. 57.
    Scopinaro N, Gianetta E, Adani GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery 1996;119:261–268.CrossRefPubMedGoogle Scholar
  58. 58.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–1737.CrossRefPubMedGoogle Scholar
  59. 59.
    Pender C, Goldfine ID, Tanner CJ, et al. Muscle insulin receptor concentrations in obese patients post bariatric surgery: relationship to hyperinsulinemia. Int J Obes Relat Metab Disord 2004;28:363–369.CrossRefPubMedGoogle Scholar
  60. 60.
    Gray RE, Tanner CJ, Pories WJ, MacDonald KG, Houmard JA. Effect of weight loss on muscle lipid content in morbidly obese subjects. Am J Physiol Endocrinol Metab 2003; 284:E726–E732.CrossRefPubMedGoogle Scholar
  61. 61.
    Houmard JA, Tanner CJ, Yu C, et al. Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl-CoAs in morbidly obese subjects. Diabetes 2002;51: 2959–2963.CrossRefPubMedGoogle Scholar
  62. 62.
    Pories WJ. Diabetes: the evolution of a new paradigm. Ann Surg 2004;239:12–13.PubMedCentralCrossRefPubMedGoogle Scholar
  63. 63.
    Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003;138: 389–396.CrossRefPubMedGoogle Scholar
  64. 64.
    Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001;86:5083–5086.CrossRefPubMedGoogle Scholar
  65. 65.
    Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002;277:5667–5674.CrossRefPubMedGoogle Scholar
  66. 66.
    Svensson J, Lonn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998;83: 362–369.PubMedGoogle Scholar
  67. 67.
    Drucker DJ. Glucagon-like peptide-1 and the islet β-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003;144:5145–5148.CrossRefPubMedGoogle Scholar
  68. 68.
    Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824–830.CrossRefPubMedGoogle Scholar
  69. 69.
    Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929–2940.CrossRefPubMedGoogle Scholar
  70. 70.
    Naslund E, Gryback P, Backman L, et al. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998;43:945–952.CrossRefPubMedGoogle Scholar
  71. 71.
    Naslund E, Backman L, Holst JJ, Theodorsson E, Hellstrom PM. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 1998;8:253–260.CrossRefPubMedGoogle Scholar
  72. 72.
    Naslund E, Gryback P, Hellstrom PM, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997;21:387–392.CrossRefPubMedGoogle Scholar
  73. 73.
    Sarson DL, Scopinaro N, Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 1981;5:471–480.PubMedGoogle Scholar
  74. 74.
    Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006;93:210–215.CrossRefPubMedGoogle Scholar
  75. 75.
    Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243:108–114.PubMedCentralCrossRefPubMedGoogle Scholar
  76. 76.
    Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941–948.CrossRefPubMedGoogle Scholar
  77. 77.
    Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650–654.CrossRefPubMedGoogle Scholar
  78. 78.
    Andrews NJ, Irving MH. Human gut hormone profiles in patients with short bowel syndrome. Dig Dis Sci 1992;37: 729–732.CrossRefPubMedGoogle Scholar
  79. 79.
    Greenway SE, Greenway FL, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 2002;137:1109–1117.CrossRefPubMedGoogle Scholar
  80. 80.
    Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236:554–559.PubMedCentralCrossRefPubMedGoogle Scholar
  81. 81.
    Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg 1998;22:936–946.CrossRefPubMedGoogle Scholar
  82. 82.
    Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a nonobese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004;239:1–11.PubMedCentralCrossRefPubMedGoogle Scholar
  83. 83.
    Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004;70:1–4.PubMedGoogle Scholar
  84. 84.
    Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004;240:236–242.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Kellum JM, Kuemmerle JF, O’Dorisio TM, et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990;211:763–770.PubMedCentralCrossRefPubMedGoogle Scholar
  86. 86.
    Sorensen TI, Lauritsen KB, Holst JJ, Stadil F, Andersen B. Gut and pancreatic hormones after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Digestion 1983;26:137–145.CrossRefPubMedGoogle Scholar
  87. 87.
    Meryn S, Stein D, Straus EW. Pancreatic polypeptide, pancreatic glucagon, and enteroglucagon in morbid obesity and following gastric bypass operation. Int J Obes 1986;10:37–42.PubMedGoogle Scholar
  88. 88.
    Koopmans HS, Ferri GL, Sarson DL, Polak JM, Bloom SR. The effects of ileal transposition and jejunoileal bypass on food intake and GI hormone levels in rats. Physiol Behav 1984;33:601–609.CrossRefPubMedGoogle Scholar
  89. 89.
    Ueno T, Shibata C, Naito H, et al. Ileojejunal transposition delays gastric emptying and decreases fecal water content in dogs with total colectomy. Dis Colon Rectum 2002; 45:109–116.CrossRefPubMedGoogle Scholar
  90. 90.
    Ohtani N, Sasaki I, Naito H, Shibata C, Tsuchiya T, Matsuno S. Effect of ileojejunal transposition of gastrointestinal motility, gastric emptying, and small intestinal transit in dogs. J Gastrointest Surg 1999;3:516–523.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Panduranga Yenumula
    • 1
  • Carolina Gomes Goncalves
    • 2
  • Stacy A. Brethauer
    • 3
  • Sangeeta Kashyap
    • 4
  • Philip R. Schauer
    • 5
    • 6
  1. 1.Department of SurgeryMichigan State UniversityLansingUSA
  2. 2.Department of General SurgeryThe Cleveland Clinic FoundationClevelandUSA
  3. 3.Advanced Laparoscopic and Bariatric Surgery, Department of General SurgeryThe Cleveland Clinic FoundationClevelandUSA
  4. 4.Department of Endocrinology, Diabetes and MetabolismThe Cleveland Clinic FoundationClevelandUSA
  5. 5.Lerner College of MedicineUSA
  6. 6.Advanced Laparoscopic and Bariatric Surgery, Bariatric and Metabolic InstituteThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations